|
Onvansertib Clinical Trials
4 actively recruiting trials across 4 locations
Also known as: 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075 +2 more
Pipeline
Early 1: 1Phase 1: 1Phase 2: 1Phase 1/2: 1
Top Sponsors
- University of Maryland, Baltimore1
- University of Kansas Medical Center1
- OHSU Knight Cancer Institute1
- Mayo Clinic1
Indications
- Cancer4
- Locally Advanced Pancreatic Ductal Adenocarcinoma1
- Stage II Pancreatic Cancer AJCC v81
- Recurrent Atypical Chronic Myeloid Leukemia1
- Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified1
Kansas City, Kansas1 trial
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
The University of Kansas Cancer Center, Westwood Campus
Phase 1/2
Baltimore, Maryland1 trial
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland Greenebaum Comprehensive Cancer Center
Phase 2
Rochester, Minnesota1 trial
Portland, Oregon1 trial
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Early 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.